Xiangmei Ye^1,2,3, Baoyi Yang⁴, Xin Zhang⁵, Luyuan Yang¹, Likun Zhang⁵, Qin Ren¹, Xiaobing Li¹, Leiguang Feng¹, Lanlan Wei^3,6,7,*, Peng Song¹, Yuqing Ye⁸, Xin Lian⁹, Yujuan Gao⁹, Haidi Tang¹, Zhiyu Liu¹

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.068814 - 30 December 2025

Abstract Objectives: Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia and Philadelphia-like B-cell acute lymphoblastic leukemia (Ph+/Ph-like ALL) constitute the majority of relapsed/refractory B-ALL (R/R B-ALL) cases, highlighting an urgent need to discover new therapeutic targets. This study aims to elucidate the mechanisms underlying poor prognosis in Ph+/Ph-like ALL through transcriptome sequencing and functional cytological assays, with the goal of informing new clinical treatment strategies. Results: Transcriptomic analysis of Ph+/Ph-like ALL patients revealed that low expression of P2X Purinoceptor 1 (P2RX1) was associated with unfavorable outcomes. Specifically, patients with poor prognosis and low P2RX1 expression exhibited downregulation of… More >

Si Qin, Shu Tang, Lijiao Xie, Jianbo Zhu, Jianguo Sun^*

Oncology Research, Vol.33, No.12, pp. 4145-4154, 2025, DOI:10.32604/or.2025.068300 - 27 November 2025

Abstract Background: Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare subtype of primary non-small cell lung cancer (NSCLC), with no established treatment guidelines. We present a case of a young female with PPLELC who achieved a pathological complete response (pCR) in both primary and metastatic lesions after receiving combined immunotherapy and radiotherapy. Case description: We present a 33-year-old female patient with stage IVa (cT2bN0M1b) PPLELC. As a first-line treatment, the patient received seven cycles of nab-paclitaxel combined with toripalimab (a PD-1 inhibitor) and achieved stable disease. This was followed by toripalimab maintenance therapy for nearly 30 months.… More >

Kayce Blumenstock^1,2, Vandana Zaman^2,3, Camille Green³, Narendra L. Banik^1,2,3, Azizul Haque^1,2,3,*

BIOCELL, Vol.49, No.10, pp. 1859-1871, 2025, DOI:10.32604/biocell.2025.068773 - 22 October 2025

Abstract Fc Receptor-Like 1 (FCRL1), a member of the FCRL family, contains two immunoreceptor tyrosine-based activation motifs (ITAMs) in its cytoplasmic domain and plays a critical role in B-cell biology. Its expression begins in pre-B-cells, dynamically shifts during B-cell development, and contributes to the regulation of human B-cell activation. Notably, FCRL1 is overexpressed in subsets of naive and memory B-cells, as well as in malignant B-cells, including those in diffuse large B-cell lymphoma (DLBCL), an aggressive and often treatment-resistant hematological malignancy. Among FCRL family members, FCRL1 stands out as a promising immunotherapeutic target due to its More >

Sotirios Charalampos Diamantoudis^1,#,*, Androulla N. Miliotou^2,#, Eleftheria Galatou², Stergiani Telliou³, Konstantinos Sideris⁴, Nikolaos Grigoriadis¹, Ioannis S. Vizirianakis^1,2,*

BIOCELL, Vol.49, No.10, pp. 1799-1858, 2025, DOI:10.32604/biocell.2025.067216 - 22 October 2025

Abstract Hematological cancer stem cells (HCSCs) is a subpopulation of cells within hematological cancers that, through their characteristics, enhance malignancy and render their therapy more challenging. By uncovering the underlying mechanisms behind characteristic properties such as self-renewal, immune evasion, and conventional therapy resistance, as well as the major differences between other cancers and physiological cells, new and alternative targets can be assessed for use in existing and novel immunotherapeutic interventions. Through the evaluation of the existing literature, one can realize that there have already been several studies addressing the use of stem cell transplantation (SCT), monoclonal More > Graphic Abstract

Norbert Nass^1,2,#, Mohamad-Kamal Yaakoub^1,#, Alexandra-Victorita Simion³, Hartmut Kroll⁴, Sabine Westphal³, Judith Pannier¹, Gerhard Behre^1,*

Oncology Research, Vol.33, No.10, pp. 2923-2935, 2025, DOI:10.32604/or.2025.067561 - 26 September 2025

Abstract Background: Patients with hemato-oncological malignancies may respond insufficiently to vaccination, especially in terms of antibody titer. The antibody response depends on the type of malignancy as well as the type and timing of treatment. We intended to evaluate this using real-world data from patients of our regional hospital. This study also considers the role of immune status, including T-cell activation markers, in predicting vaccination success. Methods: Seventeen patients of our hospital having a hematological malignancy were included in this study, including myeloma, lymphoma, as well as acute myeloid leukemia (AML) and chronic lymphoid leukemia (CLL).… More >

Hande İştar^1,#,*, Buğra Harmandar¹, Melike Korkmaz Toker², Fulden Cantaş Türkiş³

Congenital Heart Disease, Vol.20, No.4, pp. 503-517, 2025, DOI:10.32604/chd.2025.068540 - 18 September 2025

Abstract Background: The neutrophil–lymphocyte ratio (NLR) is a simple, cost-effective marker of systemic inflammation. This study aims to evaluate the association between perioperative NLR and postoperative outcomes in pediatric patients undergoing congenital heart surgery with cardiopulmonary bypass (CPB). Methods: We retrospectively reviewed 70 patients under 18 years of age who underwent surgery between 2018 and 2023. NLR was measured preoperatively and on postoperative days (POD) 0, 1, 2, 3, and 6. Receiver operating characteristic analysis identified optimal cutoffs, and associations with postoperative outcomes were assessed. Results: The preoperative NLR cutoff of 1.14 (AUC = 0.75) was associated with More >

Filomena Emanuela Laddaga¹, Pamela Pinto², Bruna Daraia², Antonio D’amato^3,4, Stella D’oronzo^3,5, Stefano Martinotti^3,6,*, Francesco Gaudio^2,3,*

BIOCELL, Vol.49, No.7, pp. 1185-1206, 2025, DOI:10.32604/biocell.2025.063572 - 25 July 2025

Abstract Checkpoint inhibitors, particularly programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors, have significantly advanced the treatment of Hodgkin lymphoma (HL), especially in relapsed or refractory cases. However, challenges such as resistance, immune-related adverse events (irAEs), and the need for effective patient selection remain. This review aims to explore the mechanisms of resistance to checkpoint inhibitors, including alterations in the tumor microenvironment, loss of antigen presentation, and T-cell exhaustion. Overcoming resistance may involve combination therapies, such as pairing PD-1 inhibitors with other immune checkpoint inhibitors or targeted therapies like Brentuximab vedotin. Additionally, next-generation inhibitors targeting molecules like More >

Alexander Blagov^1,*, Michael Bukrinsky², Aleksandra Utkina³, Gulalek Babayeva⁴, Vasily Sukhorukov¹, Alexander Orekhov⁵

BIOCELL, Vol.49, No.7, pp. 1125-1140, 2025, DOI:10.32604/biocell.2025.062821 - 25 July 2025

Abstract Eosinophils are multifunctional granulocytes that contribute to the initiation and modulation of inflammation. Accumulating evidence suggests that eosinophils are adaptable leukocytes that orchestrate the resolution of inflammatory responses. The most prevalent chronic inflammatory illness, rheumatoid arthritis (RA), is typified by persistent synovitis that makes it hard for the disease to go away on its own. Interestingly, a unique subset of eosinophils known as regulatory eosinophils has been found in RA patients’ synovium, especially while the disease is in remission. Pro-resolving signatures of regulatory eosinophils in the synovium are distinct from those of their lung counterparts. More >

MELISSA SáNCHEZ-RODRíGUEZ^1,2, ROBERTO LAZZARINI-LECHUGA³, VERóNICA SOUZA-ARROYO^1,4, LETICIA BUCIO-ORTIZ^1,4, ROXANA U. MIRANDA-LABRA^1,4, MONSERRAT GERARDO-RAMíREZ¹, ARACELI PáEZ-ARENAS⁵, MOISES VERGARA-MENDOZA⁶, MARíA CONCEPCIóN GUTIéRREZ-RUIZ^1,4, ALEJANDRO ESCOBEDO-CALVARIO^1,2,*, LUIS E. GOMEZ-QUIROZ^1,4,*

Oncology Research, Vol.33, No.8, pp. 2075-2084, 2025, DOI:10.32604/or.2025.064899 - 18 July 2025

Abstract Background: Growth differentiation factor 11 (GDF11), a transforming growth factor-beta superfamily member, is a crucial protein involved in many differentiation processes in embryogenesis and morphogenesis, and it has been extensively characterized due to its capacity to target poorly differentiated cells, including transformed or cancer cells. Aim: In the present work, we aimed to describe the effects on migration, proliferation, and metabolism in the T-cell acute lymphoblastic leukemia-derived cell line Jurkat. Methods: Based on previous evidence, we analyzed metabolic changes exerted by GDF11 and its relationship with the aggressive phenotype. Results: We found a profound impact on More >

Weiwei Chen¹, Xiaodie Zhou², Huiyu Li¹, Yuchen Yang¹, Lu Lu¹, Chunyan Zhu¹, Rong Fang¹, Xiaoyuan Chu¹, Shuping Zhou^3,*, Qian Sun^1,*

Oncology Research, Vol.33, No.8, pp. 2123-2139, 2025, DOI:10.32604/or.2025.063484 - 18 July 2025

Abstract Background: Primary bone marrow diffuse large B-cell lymphoma (PBM-DLBCL) represents an uncommon yet clinically aggressive hematologic malignancy. Despite its significant clinical impact, this entity lacks standardized diagnostic criteria in current WHO classifications. Methods: We performed a retrospective analysis of 55 PBM-DLBCL cases from our institutional database and published literature (2001–2022) to characterize disease features and identify prognostic factors, with particular focus on assessing how different treatment regimens influence therapeutic efficacy and long-term outcomes. Results: The data suggested a potential link between international prognostic index (IPI) scores and poorer survival, albeit without conclusive statistical evidence (p = More >